The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. The successful candidate will serve as a key medical leader, partnering closely with Clinical Operations, Regulatory Affairs, Biostatistics, Drug Safety, Translational Medicine, Research, and Medical Affairs to advance innovative therapies through development.